dm+d
18036811000001106
Articles
Parkinson’s disease medicines in swallowing difficulties
13 June 2022
Guidance to help you ensure your patients with Parkinson’s Disease are able to get the most from their medicines if they develop swallowing difficultiesMedicine Compliance Aid Stability
generic
Teva UK Ltd
Teva UK Ltd
generic
Capsules 12.5/50, 25/100, 50/200
R2 · Red 2 Drug is not suitable for CAs due to theoretical reasons that cannot be mitigated.
Unsuitable
Complex dosing regime. Protect from moisture. Unsuitable.
30 June 2022
Madopar
Roche Products Ltd
Roche Products Ltd
Madopar
Capsules 62.5mg, 125mg, 250mg
R2 · Red 2 Drug is not suitable for CAs due to theoretical reasons that cannot be mitigated.
Unsuitable
Complex dosing regime. Protect from moisture. Unsuitable.
30 June 2022
Madopar Dispersible
Roche Products Ltd
Roche Products Ltd
Madopar Dispersible
Tablets dispersible 50/12.5 & 100/25
R1 · Red 1 Stability data indicates that the drug is not suitable for CAs.
Unsuitable
Dispersible tablet so unsuitable.
7 November 2022
Madopar CR
Roche Products Ltd
Roche Products Ltd
Madopar CR
Capsules m/r 125mg
R2 · Red 2 Drug is not suitable for CAs due to theoretical reasons that cannot be mitigated.
Unsuitable
Complex dosing regime. Protect from moisture. Unsuitable.
30 June 2022
Lactation Safety Information
Benserazide + levodopa
Benserazide + levodopa
Low levels anticipated in milk due to the drug's properties
Limited published evidence of safety of levodopa and no published evidence for benserazide
May interfere with lactation although less likely if lactation established. Monitor milk production
29 July 2020